Program
plecanatide
Also written as “Plecanatide”, “SP-304 0.3 mg” and “SP-304 1.0 mg”.
Its studies are mostly in Constipation · Irritable Bowel Syndrome · Bronchiolitis Obliterans Syndrome, led by 2 companies.
Drug pagePlecanatide: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companiesits history only | 121 open or running | phase 3since Sep 6, 2011 | Jan 12, 2010 | Oct 18, 2027phase 2 · NCT07723924 |
| Shandong Luoxin Pharmaceutical Group Stock | 10 open or running | phase 3since Nov 4, 2021 | Nov 4, 2021 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shandong Luoxin Pharmaceutical Group Stock only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2021First study: phase 3 study in Functional ConstipationFirst studyNCT05151328 · 648 enrolled · China
TargetBeta
“An agonist of intestinal guanylate cyclase type C (GC-C) which is almost structurally identical to human uroguanylin, with laxative and anti-nociceptive activities”NCIt, by rule
“Heat-stable enterotoxin receptor agonist”ChEMBL 37, by rule
Studies
The one study Shandong Luoxin Pharmaceutical Group Stock leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05151328Functional Constipation · China | 3 | Completed | Oct 12, 2023 | 648 |
How it is read
Names in the registry
- “Plecanatide”, 10 entries
- “plecanatide”, 2 entries
- “SP-304 0.3 mg”, 1 entry
- “SP-304 1.0 mg”, 1 entry
- “SP-304 3.0 mg”, 1 entry
Conditions, from the studies’ own filings
- Constipation, 11 studies
- Irritable Bowel Syndrome, 1 study
- Bronchiolitis Obliterans Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.